{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:43:15Z","timestamp":1789267395452,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16440"],"award-info":[{"award-number":["19K16440"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008673","name":"Yasuda Memorial Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jphs.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T11:56:47Z","timestamp":1621771007000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia"],"prefix":"10.1016","volume":"147","author":[{"given":"Megumi","family":"Kikuya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Furuichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Toyooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousei","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jphs.2021.05.001_bib1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jphs.2021.05.001_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1634\/theoncologist.8-6-531","article-title":"Activation of tyrosine kinases in cancer","volume":"8","author":"Vlahovic","year":"2003","journal-title":"Oncol"},{"issue":"8","key":"10.1016\/j.jphs.2021.05.001_bib3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jphs.2021.05.001_bib4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/1097-0142(19861115)58:10<2260::AID-CNCR2820581017>3.0.CO;2-U","article-title":"Expression of epidermal growth factor receptors in human lung tumors","volume":"58","author":"Hwang","year":"1986","journal-title":"Cancer"},{"issue":"3\u20134","key":"10.1016\/j.jphs.2021.05.001_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10911-014-9329-5","article-title":"The HER2 signaling network in breast cancer--like a spider in its web","volume":"19","author":"Dittrich","year":"2014","journal-title":"J\u00a0Mammary Gland Biol Neoplasia"},{"issue":"4","key":"10.1016\/j.jphs.2021.05.001_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.semcancer.2013.04.001","article-title":"The molecular basis of targeting protein kinases in cancer therapeutics","volume":"23","author":"Tsai","year":"2013","journal-title":"Semin Canc Biol"},{"issue":"8","key":"10.1016\/j.jphs.2021.05.001_bib7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jphs.2021.05.001_bib8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jphs.2021.05.001_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jphs.2021.05.001_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228529","article-title":"Tyrosine kinase receptors in oncology","volume":"21","author":"Esteban-Villarrubia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2021.05.001_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2007.1.371","article-title":"Medical management of CML","author":"Shah","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jphs.2021.05.001_bib12","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1038\/cddis.2013.60","article-title":"Targeting cellular metabolism to improve cancer therapeutics","volume":"4","author":"Zhao","year":"2013","journal-title":"Cell Death Dis"},{"issue":"5930","key":"10.1016\/j.jphs.2021.05.001_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jphs.2021.05.001_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cas.13442","article-title":"Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells","volume":"109","author":"Hirao","year":"2018","journal-title":"Canc Sci"},{"key":"10.1016\/j.jphs.2021.05.001_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fphar.2012.00104","article-title":"Expression of the aldo-ketoreductases AKR1B1 and AKR1B10 in human cancers","volume":"3","author":"Laffin","year":"2012","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.jphs.2021.05.001_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/CAD.0b013e3283448df0","article-title":"Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms","volume":"22","author":"Matsunaga","year":"2011","journal-title":"Anti Canc Drugs"},{"issue":"4","key":"10.1016\/j.jphs.2021.05.001_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03602530802431439","article-title":"The aldo-keto reductase superfamily and its role in drug metabolism and detoxification","volume":"40","author":"Barski","year":"2008","journal-title":"Drug Metab Rev"},{"issue":"6","key":"10.1016\/j.jphs.2021.05.001_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.exer.2006.08.002","article-title":"Focus on molecules: aldose reductase","volume":"85","author":"Anil Kumar","year":"2007","journal-title":"Exp Eye Res"},{"issue":"20","key":"10.1016\/j.jphs.2021.05.001_bib19","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.1021\/acs.jmedchem.7b00830","article-title":"Synthesis of potent and selective inhibitors of aldo-keto reductase 1B10 and their efficacy against proliferation, metastasis, and cisplatin resistance of lung cancer cells","volume":"60","author":"Endo","year":"2017","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.jphs.2021.05.001_bib20","doi-asserted-by":"crossref","first-page":"18699","DOI":"10.1038\/s41598-019-55296-3","article-title":"Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner","volume":"9","author":"Shiratori","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jphs.2021.05.001_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1900\/RDS.2004.1.165","article-title":"Involvement of oxidative stress and the JNK pathway in glucose toxicity","volume":"1","author":"Kaneto","year":"2004","journal-title":"Rev Diabet Stud"},{"issue":"1","key":"10.1016\/j.jphs.2021.05.001_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2009.05.009","article-title":"Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids","volume":"487","author":"Endo","year":"2009","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jphs.2021.05.001_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1196\/annals.1333.014","article-title":"Dicarbonyl intermediates in the maillard reaction","volume":"1043","author":"Thornalley","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.jphs.2021.05.001_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1254\/jphs.FP0040404","article-title":"Transcription factor Nrf2 regulates promoter activity of mouse aldose reductase (AKR1B3) gene","volume":"97","author":"Nishinaka","year":"2005","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"1\u20133","key":"10.1016\/j.jphs.2021.05.001_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cbi.2011.01.026","article-title":"Regulation of aldo-keto reductase AKR1B10 gene expression: involvement of transcription factor Nrf2","volume":"191","author":"Nishinaka","year":"2011","journal-title":"Chem Biol Interact"},{"issue":"2","key":"10.1016\/j.jphs.2021.05.001_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.niox.2011.02.007","article-title":"The Keap1-Nrf2 system as an in\u00a0vivo sensor for electrophiles","volume":"25","author":"Uruno","year":"2011","journal-title":"Nitric Oxide : Biol Chem"},{"issue":"1","key":"10.1016\/j.jphs.2021.05.001_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1042\/BJ20111648","article-title":"Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation","volume":"443","author":"Xue","year":"2012","journal-title":"Biochem J"},{"issue":"11","key":"10.1016\/j.jphs.2021.05.001_bib28","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1021\/bi00011a027","article-title":"Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose","volume":"34","author":"Wells-Knecht","year":"1995","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.jphs.2021.05.001_bib29","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.tiv.2009.09.001","article-title":"Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression","volume":"23","author":"Frydrych","year":"2009","journal-title":"Toxicol Vitro"},{"issue":"16","key":"10.1016\/j.jphs.2021.05.001_bib30","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.1111\/jcmm.15581","article-title":"Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential","volume":"24","author":"Khayami","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"issue":"22","key":"10.1016\/j.jphs.2021.05.001_bib31","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1016\/j.febslet.2013.09.031","article-title":"Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111)","volume":"587","author":"Zhang","year":"2013","journal-title":"FEBS Lett"},{"issue":"5","key":"10.1016\/j.jphs.2021.05.001_bib32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.jphs.2021.05.001_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133134","article-title":"Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells","volume":"20","author":"De Rosa","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jphs.2021.05.001_bib34","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.jphs.2021.05.001_bib35","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bjc.6604946","article-title":"Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study","volume":"100","author":"Klawitter","year":"2009","journal-title":"Br J Canc"},{"issue":"1","key":"10.1016\/j.jphs.2021.05.001_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2007.03.015","article-title":"Reactive carbonyls and oxidative stress: potential for therapeutic intervention","volume":"115","author":"Ellis","year":"2007","journal-title":"Pharmacol Ther"},{"issue":"19","key":"10.1016\/j.jphs.2021.05.001_bib37","doi-asserted-by":"crossref","first-page":"11429","DOI":"10.1074\/jbc.273.19.11429","article-title":"Identification and characterization of a novel human aldose reductase-like gene","volume":"273","author":"Cao","year":"1998","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"10.1016\/j.jphs.2021.05.001_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s13340-015-0206-2","article-title":"Evidence-based practice guideline for the treatment for diabetes in Japan 2013","volume":"6","author":"Tajima","year":"2015","journal-title":"Diabetol Int"},{"issue":"1\u20132","key":"10.1016\/j.jphs.2021.05.001_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0027-5107(02)00232-4","article-title":"DNA damage by carbonyl stress in human skin cells","volume":"522","author":"Roberts","year":"2003","journal-title":"Mutat Res"},{"key":"10.1016\/j.jphs.2021.05.001_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fonc.2017.00085","article-title":"The KEAP1-NRF2 system in cancer","volume":"7","author":"Taguchi","year":"2017","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jphs.2021.05.001_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/MCB.26.1.221-229.2006","article-title":"Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1","volume":"26","author":"Kobayashi","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.jphs.2021.05.001_bib42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1592\/phco.28.5.646","article-title":"Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy","volume":"28","author":"Ramirez","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jphs.2021.05.001_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1254\/jjp.88.123","article-title":"Gene expression of enzymes comprising the polyol pathway in various rat tissues determined by the competitive RT-PCR method","volume":"88","author":"Maekawa","year":"2002","journal-title":"Jpn J Pharmacol"},{"issue":"9","key":"10.1016\/j.jphs.2021.05.001_bib44","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/BF00352373","article-title":"Molecular genetic analysis of the human sorbitol dehydrogenase gene","volume":"6","author":"Carr","year":"1995","journal-title":"Mamm Genome"},{"issue":"1","key":"10.1016\/j.jphs.2021.05.001_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/FPC.0000000000000022","article-title":"Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line","volume":"24","author":"Skoglund","year":"2014","journal-title":"Pharmacogenetics Genom"},{"issue":"6","key":"10.1016\/j.jphs.2021.05.001_bib46","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"Pt 3","key":"10.1016\/j.jphs.2021.05.001_bib47","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1042\/bj20021818","article-title":"Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism","volume":"373","author":"Crosas","year":"2003","journal-title":"Biochem J"},{"issue":"30","key":"10.1016\/j.jphs.2021.05.001_bib48","doi-asserted-by":"crossref","first-page":"20813","DOI":"10.1074\/jbc.M114.575464","article-title":"Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma","volume":"289","author":"Makinoshima","year":"2014","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.jphs.2021.05.001_bib49","first-page":"1108","article-title":"Cisplatin suppresses the growth and proliferation of breast and cervical cancer cell lines by inhibiting integrin beta5-mediated glycolysis","volume":"6","author":"Wang","year":"2016","journal-title":"Am J Cancer Res"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:00:50Z","timestamp":1761163250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861321000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1347861321000438"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2021.05.001","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}